Valneva SE (VALN) Cost of Revenue (2021 - 2026)
Valneva SE (VALN) posted quarterly Cost of Revenue of $29.8 million for Q1 2026, up 13.61% year-on-year from $26.2 million in Q1 2025, and down 27.42% on a QoQ basis from $41.0 million in Q4 2025.
Valneva SE (VALN) Cost of Revenue (2021 - 2026) Analysis & Trends
Valneva SE (VALN) has reported Cost of Revenue for 6 consecutive years, with $29.8 million the latest figure, recorded in Q1 2026.
- Quarterly Cost of Revenue rose 13.61% year-over-year to $29.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $125.5 million (up 10.92% YoY) and the FY2025 annual result came in at $121.9 million, up 8.73% from the prior year.
- Cost of Revenue eased to $29.8 million in Q1 2026 per VALN's latest filing, from $41.0 million in the prior quarter.
- Over the last five years, Cost of Revenue for VALN reached as high as $179.4 million in Q2 2022 and fell as low as $15.8 million in Q1 2022.
- A 5-year average of $44.0 million and a median of $29.2 million in 2024 frame the typical range for Cost of Revenue.
- Annual changes were most pronounced in 2022 — Cost of Revenue soared 683.08% — and 2023, when it plunged 78.84%.
- Year by year, Cost of Revenue stood at $138.5 million in 2022, then sank by 78.59% to $29.7 million in 2023, then gained by 4.48% to $31.0 million in 2024, then jumped by 32.46% to $41.0 million in 2025, then decreased by 27.42% to $29.8 million in 2026.
- According to Business Quant data, Cost of Revenue over the past three periods registered $29.8 million, $41.0 million, and $27.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 167.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 392.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 296.00 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 145.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Valneva SE | 839.21 Mn | 719.43 Mn | 5.38 Mn | 29.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.79 Mn |
| Mar 31, 2026 | 29.79 Mn |
| Dec 31, 2025 | 41.05 Mn |
| Dec 31, 2025 | 41.05 Mn |
| Sep 30, 2025 | 27.20 Mn |
| Sep 30, 2025 | 27.20 Mn |
| Jun 30, 2025 | 27.45 Mn |
| Jun 30, 2025 | 27.45 Mn |
| Mar 31, 2025 | 26.22 Mn |
| Mar 31, 2025 | 26.22 Mn |
| Dec 31, 2024 | 30.99 Mn |
| Dec 31, 2024 | 30.99 Mn |
| Sep 30, 2024 | 29.22 Mn |
| Sep 30, 2024 | 29.22 Mn |
| Jun 30, 2024 | 26.71 Mn |
| Jun 30, 2024 | 26.71 Mn |
| Mar 31, 2024 | 25.22 Mn |
| Mar 31, 2024 | 25.22 Mn |
| Dec 31, 2023 | 29.66 Mn |
| Dec 31, 2023 | 29.66 Mn |